Abstract 466P
Background
Extracellular matrix (ECM) plays a key role in tumorigenesis and progression. Collagen XII, expressed by the COL12A1 gene, is an important component of the ECM. COL12A1 is associated with tumorigenesis and poor prognosis in several cancers, but its role in breast cancer (BC) is unclear, especially the different expression between primary and metastasic foci of BC has not been reported.
Methods
We analyzed the expression of COL12A1 in tumor tissue and normal tissue, plotted a Kaplan-Meier curve by GEPIA, and analyzed mutation by COSMIC and cBioPortal in BC. PPI, GGI and pathway and process enrichment analysis were performed by STRING and Metascape. GeneMANIA was used to map gene interaction networks. BC cases with paired primary and metastatic foci were found out from TCGA database for analyzing different expression of COL12A1 in primary and metastatic foci. Immunohistochemical (IHC) staining was performed in paraffin tissue samples of paired primary lesion and lung metastases from triple-negative breast cancer (TNBC) patients.
Results
The results showed that COL12A1 in BC tissues was upregulated and was associated with poor prognosis of BC and the Luminal A+Luminal B subgroup. 3.04% of BC patients had COL12A1 gene alteration. Missense substitution (37.59%) was the most frequent mutation type. Among the 10 related genes, COL3A1, COL5A2, MMP12, P4HA1, P4HA2, P4HA3 and SERPINH1 were significantly upregulated in tumor tissue. The 20 most relevant genes in the GGI network are COL11A1, ID1, COL8A1, MMP9, COL5A1, MMP2, ISLR, LUM, COL7A1, COL3A1, COL1A2, MMP3, COL10A1, COL6A1, COL11A2, COL8A2, MMP8, MMP12. SERPINH1 and MMP13, which are enriched in several pathways including collagen degradation, collagen formation, collagen metabolic process, endodermal cell differentiation, collagen fibril organization and so on. Furthermore, analysis of paired cases from the TCGA-BRCA database revealed that COL12A1 was expressed with higher level in primary foci than metastatic foci. IHC staining revealed that the expression of COL12A1 was upregulated in primary foci of TNBC.
Conclusions
In conclusion, COL12A1 may be a poor prognostic predictor and a specific therapeutic target for primary foci in BC, especially in TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Suzhou Science and Technology Developing Projects (SKYD2022083, SYSD2020079 and SYSD2020075).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1301P - A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
Presenter: Rianne Vaes
Session: Poster session 04
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
1307P - The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Presenter: Lee Robertson
Session: Poster session 04
1308P - Diameter threshold for lung nodules at low-dose CT screening: Chinese population screening experience
Presenter: YE WENJUN
Session: Poster session 04
1309P - Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Presenter: Laura Sellmer
Session: Poster session 04
1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Presenter: Xiwen Liu
Session: Poster session 04
1311P - Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Presenter: Alba Santos Ramos
Session: Poster session 04